BeiGene Taps U.S. Auditor in Search for a Way to Dodge Delisting

More than half of BeiGene’s revenue for the first half of 2021 was generated in Switzerland, while 28.9% came from the Chinese mainland.

While regulators in Beijing and Washington debate how to settle a long-running audit standoff, some Chinese companies are blazing their own trails in search of a way to avoid getting kicked off American stock exchanges.

Chinese biotechnology company BeiGene Ltd. hired Boston-based accounting firm Ernst & Young LLP as the principal auditor of its financial statements to be filed with the U.S. Securities and Exchange Commission (SEC), replacing China-based Ernst & Young Hua Ming LLP.

You've accessed an article available only to subscribers

Subscribe today for just $.99.

VIEW OPTIONS